Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

Author:

Cheson Bruce D.¹,Byrd John C.²,Rai Kanti R.³,Kay Neil E.⁴,O'Brien Susan M.⁵,Flinn Ian W.⁶,Wiestner Adrian⁷,Kipps Thomas J.⁸

Affiliation:

1. Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

2. The Ohio State University, Columbus, OH

3. Long Island Jewish Medical Center, New Hyde Park, NY

4. Mayo Clinic, Rochester, MN

5. The University of Texas MD Anderson Cancer Center, Houston, TX

6. Sarah Cannon Research Institute, Nashville, TN

7. National Institutes of Health, Bethesda, MD

8. Moores Cancer Center, University of California San Diego, San Diego, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

Reference20 articles.

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21